Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/33848462/
1 Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: [email protected]. 2 Centro de Hematologia e Oncologia, Hospital Mãe de Deus, Porto Alegre, Brazil. 3...
-
Mark Fesler4yrIn a good prognostic subset of relapsed FL, pi3k copa added a pfs gain to rituxan therapy with manageable aes
Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/30528964/
Chimeric antigen receptor (CAR) T-cell therapy is an effective new treatment for hematologic malignancies. Two CAR T-cell products are now approved for clinical use by the U.S. FDA: tisagenlecleucel for...
-
DLBCL Connect4yrKey Points • The authors of this article are from the National Cancer institute. They noted that although cytokine release syndrome (CRS) and neurological toxicity are widespread barriers to CAR T-cell therapy, Show More
-
Mark Fesler4yrA nice but already dated review of car T cell landscape with a relevant focus on toxicity management
Programmed cell death protein-1 inhibitor combined with chimeric antigen receptor T cells in the treatment of relapsed refractory non-Hodgkin lymphoma: A case report - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/33869619/
1 Department of Hematology, Second Hospital of Hebei Medical University, Hebei Key Laboratory of Hematology, Shijiazhuang 050000, Hebei Province, China. 2 Central Laboratory, Hebei Senlang Biotechnology Co., Shijiazhuang 050000, Hebei...
-
Mark Fesler4yrThus far there are no proven consolidative or maintenance treatments post CaR T cell therapy, but with continued study one would hope for an emergence of therapies that enhance both Show More
Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/33683917/
doi: 10.1200/JCO.20.03433. Online ahead of print. 1 The University of Texas MD Anderson Cancer Center, Houston, TX. 2 Maria Skłodowska-Curie National Research Institute of Oncology, Kraków, Poland. 3 Levine Cancer...
-
Mark Fesler4yrIn cross trial comparison this pi3k inhibitor appears to have less toxicity than its predecessors ...will be nice to see if randomized comparative data emerged to prove this
Diffuse large B-cell lymphoma: new targets and novel therapies - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/33820908/
Newer, more effective and non-cytotoxic therapies are an unmet need for patients with diffuse large B-cell lymphoma (DLBCL) and other B-cell malignancies. Recently approved agents include polatuzumab with bendamustine and...
-
Mark Fesler4yrNice review on a rapidly moving therapeutic landscape... providers and patients can have hope for continued improved options in the future